| Today’s Big NewsMay 22, 2025 |
|
Thursday, May 29, 2025 | 11am ET / 8am PT While the use of precision therapies continues to expand, precision oncology drug development is facing increasing costs and complexity. It is more important than ever to implement strategies and solutions for maximizing efficiencies throughout the drug development process. Join us to learn more.
|
|
| By Fraiser Kansteiner While GSK’s Nucala may not have earned the distinction of becoming the first FDA approved biologic for COPD, the British drugmaker is confident its IL-5 antibody still has a major role to play in tackling the traditionally tough-to-treat respiratory condition. And now, the company has a fresh FDA green light to put its thesis to the test. |
|
|
|
By Nick Paul Taylor Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. With the biotech into the last year of its cash runway, Sanofi has swept in to secure a small molecule that could challenge Novartis for the Alzheimer’s disease market. |
By Fraiser Kansteiner Eight outside experts on the FDA’s Oncologic Drugs Advisory Committee delivered a unanimous ‘No’ vote on the question of whether Pfizer’s PARP inhibitor Talzenna has a favorable benefit-risk profile in metastatic castration-resistant prostate cancer patients without homologous recombination repair gene mutations. |
By Conor Hale Xi'an-based Haorui Gene will distribute PacBio's Vega benchtop system across the country while also offering product support. |
|
Thursday, June 5, 2025 | 11am ET / 8am PT Off-target binding can be a significant hurdle in the development of antibody-based therapies, with limitations of conventional screening methods being a key factor. Join our webinar to learn more about the latest approaches to specificity profiling. Register now.
|
|
By James Waldron Gilead is paying $10 million for sole ownership of arenaviral immunotherapies for hepatitis B (HBV) and HIV resulting from the company’s long-running collaboration with Hookipa Pharma. |
By Zoey Becker Patients new to branded Wegovy can access a one-month supply for $199 as part of Novo's efforts to reach more patients in a market that's been long affected by compounders. |
By Fraiser Kansteiner Samsung Biologics will devote itself fully to contract manufacturing under a plan to spin off a new investment holding company that will oversee the drugmaker’s biosimilar subsidiary Samsung Bioepis. Samsung Bio attributed the decision to industry concerns about conflicts-of-interest between its CDMO and biosimilar development businesses. |
By James Waldron Only three months after banking an eye-popping $350 million series D round, Eikon Therapeutics is blaming government funding cuts for its decision to lay off 15% of its employees. |
By Andrea Park AstraZeneca and Merck are still leading the pack when it comes to how oncologists perceive makers of cancer drugs, according to a new report from ZoomRx. |
By Gabrielle Masson French biotech OSE Immunotherapeutics is taking charge of a new project aimed at fast-tracking nanodrug development and creating new mRNA therapeutics, with 1.3 million euros ($1.47 million) in support from the French government. |
By Andrea Park Decades into its tenure as a drug seller, CSL Behring has finally dipped its toe into the waters of TV advertising. |
Fierce podcastsDon’t miss an episode |
| This week on "The Top Line," Fierce Pharma breaks down President Donald Trump’s executive order targeting drug prices and what it could mean for the industry as broader policy shifts unfold. |
|
|---|
|
|
|
Wednesday, June 11, 2025 | 11am ET / 8am PT Join us for a deep dive into the strategies and best practices for maximizing valuation by improving productivity in modern clinical trials. We'll discuss key ways to achieve tangible productivity gains, accelerate timelines, and avoid costly protocol amendments or clinical failures. Register now to learn expert tips for maximizing efficiency and effectiveness.
|
|
| WhitepaperDon’t delay your gene transfer trial’s start-up timeline by gaining the latest insights from WCG’s case study on the power of a seamless Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review process. Sponsored by: WCG |
| WhitepaperLearn how the SpyLock service can offer fast bispecific generation, reduce workload, and accelerate candidate selection. Sponsored by: Bio-Rad |
| WhitepaperWe interviewed 24 Medical Affairs leaders on the critical success factors for building a Best Practice Medical Affairs organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
